Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254317 · ClinicalTrials.gov registry record · NA
Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance
A NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT02254317 is a NA study that has completed, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 16 participants.
The verdict
NCT02254317, a NA study, has completed, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The objective is to identify the lowest effective dose of Grape Seed Extract (GSE) on glucose control in people with impaired glucose tolerance (IGT).
Interventions
- DIETARY_SUPPLEMENT 0 mg placebo
- DIETARY_SUPPLEMENT 300 mg GSE
- DIETARY_SUPPLEMENT 600 mg GSE
- DIETARY_SUPPLEMENT 900 mg GSE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-09-15 |
| Est. Completion | 2015-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02254317
The ClinicalTrials.gov registry entry for NCT02254317 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 0 mg placebo is the first listed.
NCT02254317 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02254317 about?
NCT02254317 is a clinical study titled "Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance". The objective is to identify the lowest effective dose of Grape Seed Extract (GSE) on glucose control in people with impaired glucose tolerance (IGT).
What is the current status of trial NCT02254317?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2014-09-15. Estimated completion is 2015-07-01.
What interventions are being tested in trial NCT02254317?
The interventions under investigation include: 0 mg placebo (DIETARY_SUPPLEMENT), 300 mg GSE (DIETARY_SUPPLEMENT), 600 mg GSE (DIETARY_SUPPLEMENT), 900 mg GSE (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02254317?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.